Solabia acquired SEQENS’ Botanical Actives and In-Vitro Diagnostics (IVD) activity, taking over a Limoges (France) facility known for botanical extraction and plasma/serum manufacturing, featuring integrated production for both cosmetics and diagnostics. The deal was announced as a strategic expansion of Solabia’s supply chain and scientific capabilities.
The acquired business supplies high-performance vegetal active ingredients for cosmetic formulators and diagnostic solutions used worldwide, with existing commercial relationships across both sectors. The move brings production know-how, extraction technology and IVD materials under Solabia’s operations and keeps the Limoges teams and site in active development.
For brands and labs this strengthens access to substantiated botanical actives and secures critical raw materials for diagnostics, improving supply resilience and enabling faster joint development of cross-sector solutions. The acquisition aligns with ongoing industry trends toward vertically integrated ingredient suppliers and evidence-backed botanicals.
Image Credit: Solabia
Key Themes Behind This Trend
- Vertical Integration of Botanical Supply
- Bringing extraction, formulation and manufacturing under one roof creates opportunities for suppliers to offer end-to-end validated ingredient chains that shorten development timelines and reduce supply risk.
- Cosmetic-diagnostics Convergence
- Integrated capabilities across cosmetics and IVD open space for hybrid products and shared biomarker-driven formulations that bridge personal care and clinical monitoring.
- Evidence-backed Botanical Actives
- A stronger emphasis on substantiated botanical efficacy supports the development of standardized, clinically validated plant-derived actives with traceable performance data.
Where This Applies
- Cosmetic Ingredients Manufacturing
- Consolidated extraction and formulation expertise enables manufacturers to supply high-purity, regulatory-ready botanicals tailored to premium and clinical-adjacent beauty segments.
- In-vitro Diagnostics
- Access to plasma/serum production and botanical-derived reagents presents potential for novel diagnostic kits that leverage plant-based components for stability or specificity advantages.
- Contract Manufacturing Organizations
- CMOs with combined botanical extraction and IVD capabilities can provide multi-modal contract services that reduce handoffs and accelerate prototype-to-scale transitions.
